Leading medical experts, in new guidance from the European Association for the Study of Obesity, have declared weight loss medications such as Mounjaro and Wegovy to be so effective that they should be considered the primary treatment for obesity in nearly all cases. Published in the journal Nature Medicine, this guidance praises the drugs' significant health benefits and their power to reduce the risk of associated complications like high blood pressure and type 2 diabetes, signaling a 'complete transformation' in obesity care.

Studies have demonstrated remarkable efficacy for these injectable treatments. Adults administered injections containing semaglutide, the active ingredient found in Wegovy and Ozempic, experienced an average body weight loss of 14 percent over 72 weeks. Even more impressively, those taking tirzepatide, known as Mounjaro or the 'King Kong' of weight-loss jabs, achieved a 20 percent reduction in body weight over the same duration. Dr. Andreea Ciudin, a co-first author of the guidance from the Autonomous University of Barcelona, emphasized their profound impact, stating that semaglutide and tirzepatide should be the first choice for substantial weight loss due to their effectiveness.

Beyond significant weight reduction, there is growing evidence of broader health benefits. The guidance notes that while more studies are needed, these jabs show potential for positively influencing a range of conditions, including chronic kidney disease, neurodegenerative disorders, polycystic ovary syndrome, certain cancers, and mental health conditions. This suggests their therapeutic potential extends far beyond simple weight management.

The policy implications of these drugs are also gaining traction in the UK. Health and social care secretary Wes Streeting has pledged to roll out these injections to millions more patients on the NHS, aiming to 'defeat obesity' and ensure equitable access. He highlighted the unfairness of these 'transformative' drugs being accessible only to the wealthy privately, where they can cost around £200 a month. Currently, these powerful injections are largely restricted on the NHS to the most severely obese patients or those with multiple linked diseases.

However, a universal and immediate rollout presents complex economic and logistical challenges, with concerns that it could overwhelm the NHS. Business secretary Peter Kyle has pointed out that Britain's obesity crisis costs the NHS over £11 billion annually, plus billions more in lost productivity. The guideline authors stress that the substantial cost of not treating obesity and its progression to complications should be equally weighed in health policy and clinical decision-making.

The international team of experts developed an algorithm to guide doctors in selecting the best weight loss treatment based on a patient's weight and associated conditions. Professor Barbara McGowan, a guideline author from Guy's & St Thomas's Hospital NHS Foundation Trust, London, explained that this framework is the first to be guided by the presence or absence of obesity-related complications, recognizing that weight loss is not the sole objective when complications exist. Tailoring treatment is a complex task requiring consideration of various factors, including the severity of adiposity, the presence and extent of complications, comorbidities, concurrent therapies, socioeconomic context, and patient goals. This algorithm will be regularly updated to incorporate new drugs and research findings.